Privium Fund Management B.V. Has $1.28 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Key Points

• Privium Fund Management B.V. reduced its stake in Roivant Sciences by 41.1%, owning 126,923 shares valued at approximately $1.28 million after the sale.
• Several institutional investors increased their holdings in Roivant Sciences, with Russell Investments Group Ltd. amplifying its position by 478.6% during the last quarter.
• Roivant Sciences reported a net loss of ($0.31) earnings per share, missing the consensus estimate by ($0.15), and had a revenue of only $7.57 million compared to expectations of $62.17 million.

Privium Fund Management B.V. reduced its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 41.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,923 shares of the company's stock after selling 88,583 shares during the period. Roivant Sciences comprises about 0.3% of Privium Fund Management B.V.'s investment portfolio, making the stock its 29th largest holding. Privium Fund Management B.V.'s holdings in Roivant Sciences were worth $1,281,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. FMR LLC raised its holdings in Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after acquiring an additional 156,527 shares in the last quarter. Patient Square Capital LP raised its holdings in Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock worth $147,638,000 after acquiring an additional 251,535 shares in the last quarter. Two Seas Capital LP raised its holdings in Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock worth $120,285,000 after acquiring an additional 442,914 shares in the last quarter. Invesco Ltd. raised its holdings in Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after acquiring an additional 3,159,603 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Roivant Sciences by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company's stock worth $91,968,000 after acquiring an additional 26,727 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Roivant Sciences

In other news, CEO Eric Venker sold 100,000 shares of the company's stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $11.52, for a total value of $1,152,000.00. Following the transaction, the chief executive officer owned 1,462,223 shares of the company's stock, valued at approximately $16,844,808.96. This represents a 6.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $11.46, for a total value of $6,612,500.22. Following the completion of the transaction, the insider directly owned 37,284,108 shares in the company, valued at $427,275,877.68. The trade was a 1.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,464,462 shares of company stock worth $39,228,856 in the last 90 days. Corporate insiders own 10.80% of the company's stock.

Roivant Sciences Trading Down 0.4%

NASDAQ:ROIV traded down $0.05 on Friday, hitting $11.31. The company's stock had a trading volume of 2,910,651 shares, compared to its average volume of 5,053,894. The stock has a fifty day moving average of $11.27 and a two-hundred day moving average of $10.86. The firm has a market capitalization of $7.69 billion, a P/E ratio of -45.24 and a beta of 1.15. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The business had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative net margin of 225.71% and a negative return on equity of 14.76%. During the same quarter in the prior year, the company earned ($0.23) EPS. As a group, sell-side analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ROIV shares. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, June 18th. The Goldman Sachs Group upgraded Roivant Sciences to a "strong-buy" rating and set a $19.00 target price on the stock in a report on Thursday, July 10th.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.